Abstract
Objectives To assess the validity of the prophylactic use of pirarubicin ([2'R]-4-O-tetrahydropyranyl-doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. Patients and methods The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. Results The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73%. Conclusion The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side-effects.
| Original language | English |
|---|---|
| Pages (from-to) | 802-804 |
| Number of pages | 3 |
| Journal | BJU International |
| Volume | 86 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Absorption
- Intravesical instillation
- Pirarubicin
- Superficial bladder cancer
- Transurethral resection
ASJC Scopus subject areas
- Urology
Cite this
The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. / Yamamoto, Yumiko; Nasu, Yasutomo; Saika, T.; Akaeda, T.; Tsushima, T.; Kumon, H.
In: BJU International, Vol. 86, No. 7, 2000, p. 802-804.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer
AU - Yamamoto, Yumiko
AU - Nasu, Yasutomo
AU - Saika, T.
AU - Akaeda, T.
AU - Tsushima, T.
AU - Kumon, H.
PY - 2000
Y1 - 2000
N2 - Objectives To assess the validity of the prophylactic use of pirarubicin ([2'R]-4-O-tetrahydropyranyl-doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. Patients and methods The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. Results The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73%. Conclusion The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side-effects.
AB - Objectives To assess the validity of the prophylactic use of pirarubicin ([2'R]-4-O-tetrahydropyranyl-doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. Patients and methods The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. Results The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73%. Conclusion The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side-effects.
KW - Absorption
KW - Intravesical instillation
KW - Pirarubicin
KW - Superficial bladder cancer
KW - Transurethral resection
UR - http://www.scopus.com/inward/record.url?scp=0033762604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033762604&partnerID=8YFLogxK
U2 - 10.1046/j.1464-410X.2000.00911.x
DO - 10.1046/j.1464-410X.2000.00911.x
M3 - Article
VL - 86
SP - 802
EP - 804
JO - BJU International
JF - BJU International
SN - 1464-4096
IS - 7
ER -